Numerous animal models have been developed during the past 60 years to study brain tumor initiation and development. The models can be divided into 3 categories: (1) chemically induced models, (2) genetically engineered mouse (GEM) models, including virally induced models, and (3) xenograft models. Although such models have made significant contributions to our understanding of the mechanisms related to tumor initiation and progression, the knowledge gained from such models has only to a limited extent been translated into more effective treatment principles. In the literature, there are a vast number of reports showing the therapeutic efficacy of novel treatment modalities in various animal models, yet when these are further evaluated in the clinic, they fail in phase II/III clinical trials. The success of treating animal brain tumors in rodents and the failure in a clinical setting is most likely due to several factors: (1) The tumor models do not reflect the biological properties of the patient tumors, (2) the animals used do not display the same pharmacokinetics as humans^[@NOS135C1]--[@NOS135C3]^, and (3) the tumors established do not reflect the cellular heterogeneity of human tumors.

In this review, we will describe the available brain tumor model systems and set them in historical perspective. We believe this is important, since referrals to important observations made in the early days of brain tumor transplantation and animal model development are often forgotten. Then we will discuss the advantages and pitfalls of the various models used and focus on the most important challenges in an effort to delineate the model or combination of models that best reflect human disease.

Animal Models to Study Primary Brain Tumors {#s2}
===========================================

There are 2 main reasons for modeling brain tumors in animals. The first is to identify the genetic events and molecular mechanisms that contribute to oncogenesis within the central nervous system (CNS), and the second is to evaluate potential therapeutic strategies.^[@NOS135C4]^ For both applications, in vitro models are deemed insufficient. In 2000, Hanahan and Weinberg^[@NOS135C5]^ proposed that a series of defining hallmarks characterize cancers, including limitless replication potential, sustained angiogenesis, evasion of apoptosis, self-sufficiency in growth signals, insensitivity to antigrowth signals, and tissue invasion/metastasis. The significance of these traits has withstood the scrutiny of vigorous scientific investigation during the last 10 years, whereas additional hallmarks have emerged (including a cancer-specific metabolism and avoidance of immune destruction).^[@NOS135C6]^ Although, to some extent, these traits may be artificially manipulated in vitro, they all involve a complex tumor/host cellular interplay that can be modeled only in vivo. The host components involve anatomical barriers, extracellular matrix molecules, cytokines/growth factors, and cellular determinants such as endothelial cells, tissue-specific progenitor cells, and immune cells. Many in vivo brain tumor models have been established, starting with patient material transplanted into immunocompetent rodents in the 1940s and 1950s (Fig. [1](#NOS135F1){ref-type="fig"}).^[@NOS135C7]--[@NOS135C18]^ Although these early studies failed to establish reliable models due to low engraftment rates, they provided important insights into tumor biology. The experiments revealed first that the success of tumor engraftment decreases with lower histological grade^[@NOS135C19]^ and second that good transplantability correlates with poor clinical prognosis (thus, with malignancy).^[@NOS135C8]^ These early studies functionally confirmed the quality of the anterior eye chamber and the brain as immunologically privileged organs. Fig. 1.Key events in brain tumor modeling in animals. Milestones in brain tumor model development starting with transplantation of human xenografts into immunocompetent rodents in the 1940s through rodent carcinogenesis and human monolayer cell line development in the 1960s, toward the establishment of GEM models in the 1990s, and finally the establishment of xenograft models based on stem cell enrichment.

With the advent of athymic nude mice, the reliability of transplantation of different cancers, including gliomas, proved to be high.^[@NOS135C20]^ Starting from the mid- to late 1960s, efforts were made to evaluate both DNA- and RNA-containing viruses for experimental gliomagenesis (reviewed by Thomas and Graham^[@NOS135C21]^), which proved to be successful, although the application of these models has not been widespread, probably due to an uneven distribution of recombinant viruses and inconsistent tumor growth characteristics.^[@NOS135C22]^ Concomitantly with the development of chemical in vivo carcinogenesis (described below), glioma cell lines were established that could be passaged in culture without the risk of viral infection.^[@NOS135C23]^ Traditionally, both syngeneic and xenogeneic glioma models have been established as stable monolayer cell lines; however, they largely differ from human glioma biopsy material at the molecular level^[@NOS135C18],[@NOS135C24]--[@NOS135C27]^ and fail to recapitulate the full range of histological traits seen in gliomas.^[@NOS135C28]^

Already in 1978, C. B. Wilson suggested that differences in metabolism between rats and humans could account for the inconsistencies between procarbazine sensitivity observed in a rat glioma model and in patients.^[@NOS135C29]^ In the same period, other authors questioned the predictive value of inadequately characterized animal models for clinical therapy,^[@NOS135C30]^ and it became clear that glioma cell lines growing in nude mice were unreliable in predicting clinical outcomes.^[@NOS135C31]--[@NOS135C38]^ Nevertheless, due to the lack of better alternatives, therapeutic studies employing cell line--based xenografts have been the mainstay of preclinical investigations up to today. However, during the last years, the in-depth characterization of genomic alterations in gliomas has led to a better understanding of the genetic mutations and alterations that underlie the initiation and progression of several glioma subtypes.^[@NOS135C39],[@NOS135C40]^ Through the application of advanced genomic tools,^[@NOS135C41],[@NOS135C42]^ several laboratories have created and characterized GEM models of glioma based on defined genetic alterations frequently observed in human tumors. Compared to xenotransplantation models, these in vivo brain tumor models more faithfully reflect important characteristics of several glioma subtypes and have provided insights into specific genetic events that trigger tumor initiation and progression.^[@NOS135C40]^

However, at present, it is clear that most if not all of the glioma models used today fail to recapitulate the full genomic and phenotypic signatures of human tumors. Despite these limitations, the last 60 years of model development have been instrumental for our current understanding of how gliomas develop.

Chemically Induced Syngeneic Models {#s2a}
-----------------------------------

Among the chemically induced models, the rat has been one of the most widely used,^[@NOS135C43]^ and since the mid-1970s several rat brain tumor models have been developed.^[@NOS135C44]^ Murine,^[@NOS135C45]^ canine,^[@NOS135C46]^ and feline^[@NOS135C47]^ models also exist but have gained less popularity. Spontaneous brain tumors are rarely reported in animals, except in dogs, where the incidence and malignancy types are similar to those seen in humans.^[@NOS135C48]^ About 1% of the rat strains that are commonly used for research purposes develop brain tumors spontaneously,^[@NOS135C49]^ but experimental tumors may be induced by local, oral, intravenous, or transplacental exposure of *N*-nitroso compounds into adult or pregnant rats.^[@NOS135C9],[@NOS135C50]^ For instance, transplacental injection of the carcinogen *N*-ethylnitrosourea induces formation of various CNS tumors in the progeny, including glioma-like lesions.^[@NOS135C51]--[@NOS135C54]^ However, the time point for transplacental carcinogen exposure is critical, with the highest success rate observed when the fetuses are exposed 18 days after gestation.^[@NOS135C55]^ Other chemically induced rat brain tumor models include the syngeneic 9L, C6, F98, and CNS-1.^[@NOS135C44]^ In particular the cell lines 9L and C6, derived from chemically induced tumors, have frequently been used in experimental studies in vitro as well as for establishing xenografts in vivo (for review, see Barth and Kaur^[@NOS135C23]^). However, chemically induced brain tumors appear to be quite different from human gliomas and have frequently been referred to as "gliosarcomas" or "glioma-like tumors" (Fig. [2](#NOS135F2){ref-type="fig"}). It is therefore questionable how valid they are in human glioma research. In this context, it should also be emphasized that although nitrosourea induction has been very effective in inducing CNS tumors in various rat strains, induction in mice has been less successful^[@NOS135C56]^ but can be obtained by *N*-ethyl-*N*-nitrosourea exposure in p53 knockout mice.^[@NOS135C57]^ Nitrosourea-induced CNS carcinogenesis seems, therefore, also to depend on the species involved. Immunogenicity (dependent mainly on major histocompatibility \[MHC\] class I expression) and tumor histological traits show large variations among the different chemically induced models.^[@NOS135C23]^ Fig. 2.Histological features of chemically induced gliosarcoma models. (A and B) Collective infiltration of *N*-ethylnitrosourea--induced BT4C cells into the brain tissue (frequently referred to as mesenchymal chain movement). Black arrows indicate the leading edge of migrating tumor cells. (A) Green arrows mark peritumoral necrosis and microhemorrhages. (C) Growth pattern of BT4C cells in the tumor bed. (D) Region of a sarcomatous growth with elongated, spindle-shaped cells and extracellular matrix production. All scalebars are 20 µm, except A, which is 50 µm.

### Advantages and pitfalls of chemically induced models {#s2a1}

A possible utility of these models is that they may allow us to infer knowledge about chemically induced mutagenesis within the CNS. However, although many compounds have been shown to cause tumors in the rat nervous system, no single chemical agent has yet been implicated in human brain tumor development.^[@NOS135C58],[@NOS135C59]^ This discrepancy probably relates to the fact that in carcinogenesis experiments, rodents have been deliberately exposed to toxic drug doses through a single bolus injection at an early developmental stage^[@NOS135C52]^ or to several months of repeated administration as adults.^[@NOS135C50],[@NOS135C60]^ In contrast, in humans, exposure most likely occurs sporadically at trace levels. In rat carcinogenesis experiments, developing embryos were found to be 50--100 times more susceptible to tumor development than pregnant females.^[@NOS135C52]^ Thus, due to differences in chemical doses, exposure times, metabolite preferences, and kinetics among species, the chemically induced models have only provided insight into the etiology of human CNS neoplasms to a limited extent.

In our view, an advantage of chemically induced rodent cell lines grafted in syngeneic immunocompetent animals is that all arms of the immune system (innate and acquired) are present to interact with the developing tumor and also with experimental therapeutics. One drawback, however, is the observed immunogenicity of some rodent glioma cell lines, such as the C6, 9L, and T9,^[@NOS135C23]^ where spontaneous tumor rejection may mimic therapeutic efficacy, especially when evaluating treatment modalities that involve the immune system. In the C6 model, investigators have observed that 11% of the allegedly syngeneic Wistar rat hosts survived after intracerebral grafting of 10^6^ cells, but when 10^4^ cells were used, survival increased to 30%.^[@NOS135C61]^ Furthermore, when C6 cells were grafted simultaneously into the brain and the flank (inducing a systemic immune response), all the animals survived. In comparison, the 9L/Fischer rat model had a 100% penetrance at all the applied tumor cell numbers. Thus, in studies where the C6/Wistar model was applied to evaluate the effect of immune system--based therapies, the outcome is doubtful.^[@NOS135C61]^ The difficulty in this case pertains to the identity of the syngeneic strain, since some investigators claim that C6 cells are syngeneic with BDIX^[@NOS135C62],[@NOS135C63]^ or with Sprague-Dawley rats^[@NOS135C64]^ rather than with Wistar rats. However, subsequent MHC allelotyping has revealed that none of the above-mentioned strains are syngeneic with C6 cells, suggesting that the C6 line was derived from an outbred strain.^[@NOS135C65]^

Another drawback regarding these models is in their histological characteristics. Often, they display some level of invasion---however, they fail to show single cell infiltration to the contralateral hemisphere and microvascular abnormalities characteristic of human glioblastoma multiforme (GBM). Although BT4C, F98, and RG-2 tumors have all been characterized as invasive xenografts, these lesions display various extents of local collective invasion (Fig. [2](#NOS135F2){ref-type="fig"}) rather than single cell invasion involving both hemispheres, as is frequently seen in human GBM.^[@NOS135C66],[@NOS135C67]^

Another point is that most cell lines have been passaged for long time periods in culture and have therefore been subjected to a genetic drift in vitro. Thus, due to a genotypic and phenotypic homogeneity and various extents of immunogenicity, cell line--derived tumors may be overtly sensitive to certain experimental treatments, resulting in an overestimation of therapeutic efficacy.

Up to recently, syngeneic grafts were characterized only histologically and were considered appropriate if they exhibited some growth characteristics of human tumors. However, efforts to characterize these lines at the molecular level have been few.^[@NOS135C25],[@NOS135C68],[@NOS135C69]^ Such a characterization represents a crucial step to enable investigators to select the correct model to test a given drug that may interfere with a specific signal transduction pathway.

In summary, the utility of syngeneic chemically induced gliomas has been hampered by unclear documentation of their sources and by the unavailability of data relating to their genetic profile and phenotype. If one envisions the further use of these systems, a better molecular characterization is mandatory. When these results emerge, one can truly consider both the molecular signature as well as histological characteristics of the chemically induced models, and they may then be better utilized to evaluate therapeutic responses.

Xenograft Models {#s2b}
----------------

The establishment of tumors in animals by xenografting tumor material, mostly in the form of cell lines and biopsies, has been highly valuable in the search for mechanisms that determine tumor formation, growth, and progression. In particular, with the advent of immunodeficient animals, important insight has been obtained relating to the growth of human tumors within the CNS.

### Human glioma monolayer cell lines established in serum-containing media {#s2b1}

Transferral of patient biopsy material to tissue culture flasks and subsequent passaging in monolayers using serum-supplemented media were performed throughout the 1970s and 1980s to generate human glioma cell lines.^[@NOS135C70]^ In general, intracerebral inoculation of human glioma cell lines in immunodeficient animals leads to the development of tumors with typical growth characteristics, showing an expansive growth with some strands of invasion from the main tumor mass following mainly the perivascular space. However, true single cell invasion is not a common event (Fig. [3](#NOS135F3){ref-type="fig"}A). The advantages of cell line--based models are (1) good reproducibility with respect to engraftment rate and (2) reliable growth and disease progression. Moreover, immortalized cell lines are readily expanded for an unlimited number of passages in vitro, yielding vast numbers of tumor cells for experimental use. A major disadvantage of human cell line--based models is the genotypic and phenotypic deviation of the obtained lesions from the original patient tumor. Already in 1980, it was emphasized that when using cell lines, the nature of what determines tumorigenicity in the nude mouse is not clearly defined and may represent factors that are not pertinent to human tumors.^[@NOS135C21]^ Later it was shown that only 1 out of 7 human GBM cells serially transplanted in nude mice retained their chromosomal profiles,^[@NOS135C71]^ and the resulting lesions were histologically more homogeneous than their human origins.^[@NOS135C20]^ Genomic alterations in adherent serum-growing cultures often do not correspond well to the genotype of the original tumors. Even primary cultures reflect poorly the genetic imbalances seen in the tumors from which they are derived. Profiles from array comparative genomic hybridization (aCGH)^[@NOS135C27]^ as well as whole genome sequencing^[@NOS135C72]^ of commonly used GBM cell lines show profiles that are quite distinct from those typically found in primary GBM. For instance, phenotypic and gene expression alterations, clonal selection, and genetic drift occur during the adaptation of tumor cells to monolayer cultures. As an example, the prominent U87MG cell line harbors no fewer than 512 homozygously mutated genes.^[@NOS135C72]^ Fig. 3.Histological features of GBM xenograft models. (A) GBM patient biopsies may be processed to yield adherent cell lines in serum-containing medium, which results in an extensive clonal selection and cellular adaptation process. Xenografts generated from such cell lines will display angiogenic growth and well-defined borders toward the brain tissue. No single tumor-cell invasion is seen (the example here is from the U-87 glioma cell line). (B) Enzymatic dissociation of patient biopsies with subsequent culture in neurobasal serum-free medium selects for a highly tumorigenic subpopulation in human GBM. In several instances, the resulting xenografts are highly infiltrative, following white matter tracts and spreading over the corpus callosum.^[@NOS135C24]^ (C) The biopsy xenograft model maintains several tumor cell clones from the biopsy, as well as other cell types and extracellular matrix components. When passaged extensively in immunodeficient animals, the xenografts maintain their invasive growth and develop other characteristics of human GBM, such as dilated vessels, angiogenesis, and pseudopalisading necrosis. Scale bars: 100 µm.

Most often, human cell line--derived xenografts display some levels of angiogenesis and circumscribed growth with variable extents of collective tissue invasion. They show, however, limited single cell infiltration in the brain; and necroses and microvascular abnormalities characteristic of human GBM are usually absent.^[@NOS135C28],[@NOS135C71]^ Also, aberrant expression of fibrillar and basement membrane collagens occurs when GBM patient biopsies are passaged as monolayers, suggesting a certain (mesenchymal) differentiation in vitro.^[@NOS135C73],[@NOS135C74]^ The cells often coexpress glial fibrillary acidic protein (GFAP) and collagens, indicating a transdifferentiation of glioma cells rather than a selection of mesenchymal, endothelial, or GFAP-negative glioma cell populations. Integrins such as β2 are similarly upregulated in primary glioma cell cultures, attributed possibly to the involvement of cytokines or growth factors in the cell culture media.^[@NOS135C75]^ Other differences in human GBM xenografts relate to markers of immunological significance, such as changes in MHC and FasL expression and cytokine production.^[@NOS135C76]^ In conclusion, comprehensive studies show that due to genomic and transcriptomic deviations from GBM in situ, established cell lines are poor models for human tumors.^[@NOS135C24]^

### Xenografts based on human glioma--derived cell lines passaged in neurobasal medium {#s2b2}

With the reemergence of the cancer stem cell hypothesis initially suggested more than 100 years ago,^[@NOS135C77],[@NOS135C78]^ new cell culture tools have been developed for propagating cancer stem-like cells in serum-free growth media, supplemented with epidermal growth factor (EGF), fibroblast growth factor, and insulin (neurobasal media).^[@NOS135C79]--[@NOS135C81]^ The establishment of such spheres from gliomas has provided novel insight into tumor cells that show stem-cell characteristics^[@NOS135C82]--[@NOS135C85]^ and has proven to be highly successful from a variety of tumors, including pediatric gliomas^[@NOS135C83]^ and GBM.^[@NOS135C86]^

The sphere cultures have several advantages compared to monolayer cultures. First, glioma spheres have been shown to more closely reiterate the molecular makeup of the original patient tumor; furthermore, molecular profiles are more stable over time.^[@NOS135C18],[@NOS135C87],[@NOS135C88]^ At the same time, however, the derived cell populations may show considerable variations. A recent study has shown that some cell populations exhibit a stem cell--like expression profile similar to the patient tumor, while others exhibit a more mesenchymal phenotype that diverges from the original tumor.^[@NOS135C89]^ Furthermore, as in serum supplemented cultures, amplification of *EGFR* is not a common trait in the sphere cultures.^[@NOS135C87]^ Yet, spheres are highly tumorigenic and, more importantly, show variable amounts of angiogenesis and extensive invasion in vivo (Fig. [3](#NOS135F3){ref-type="fig"}B).^[@NOS135C88],[@NOS135C89]^ Recently histopathological and genomic profiles were obtained from 15 orthotopic xenografts derived from sphere cultures, where a comparison was made with the respective patient tumors. It was shown that the xenografts recapitulated the diverse histology of the patient GBM to a large extent. Moreover, the xenografts could be divided into 2 groups: a discrete nodular phenotype showing little invasion and a diffusely invasive phenotype. This indicates that different courses of tumor development may occur from xenografts established from stem cell--like cultures from different patients.^[@NOS135C90]^

The invasive cells most likely have specific molecular signatures that are either characteristic traits of a defined subpopulation within a tumor or are due to an extensive adaptive capacity of certain cells within a tumor.^[@NOS135C91]^ The culture of high-grade gliomas as neurospheres is straightforward, and proliferating spheres may occur within the first week of culture. However, neurospheres do not develop successfully from all human gliomas. In fact, some controversy exists, as the success rate varies from 10% to 20% to 100% in different laboratories.^[@NOS135C79],[@NOS135C81],[@NOS135C92]^ An alternative approach has been to adjust the serum-free cell culture system to monolayer cultures.^[@NOS135C93]^ This system has been used for the culture of some low-grade gliomas that subsequently engrafted.^[@NOS135C94]^ Yet at present there is little molecular evidence indicating that adherent cultures should be preferred to sphere cultures.^[@NOS135C95]^ However, the format of adherent cultures may be more amenable for high throughput drug screening purposes.

Clearly, the generation of tumorigenic cell populations from human gliomas through the use of neurosphere cultures has significantly advanced our knowledge of specific subpopulations within human primary tumors. Even though their phenotypes in vivo are not necessarily predictable, they now represent, in combination with engrafting tumor tissue directly into animals, an important tool to study tumorigenicity and progression of human tumors in vivo.

#### Advantages and pitfalls of human cell line xenograft models {#s2b2a}

Although cell lines in serum-containing media are readily established from human GBM, it has proven difficult to establish cell lines from low-grade gliomas, including oligodendrogliomas.^[@NOS135C96]--[@NOS135C98]^ The reason for this discrepancy is not known. What is known is that an extensive clonal selection occurs after the transfer of glioma cell supensions into serum-containing media and that a further adaptation takes place during culture. It is therefore highly questionable to what extent extracted biological information from cell line xenografts, grown in serum-supplemented media, can contribute to our understanding of human disease, since cell lines are essentially incapable of recapitulating the complex genetic and phenotypic traits of human gliomas.

With the advent of neurobasal serum-free cultures, expandable, permanent glioma cell lines are starting to show promise, although it remains to be seen whether they retain their genetic and epigenetic profiles after years of culture. Stem cell--like spheres can be propagated and amplified to yield sufficient tumor material for tissue-demanding experimental procedures, such as setting up therapeutic studies in animals. In our mind the most striking difference, compared with cultures growing in serum-supplemented media, is the ability of stem cell--like spheres to establish extensive infiltrative lesions when transplanted into CNS. This is a major improvement in malignant glioma xenograft modeling.

Moreover, low-grade gliomas may also be developed using the neurosphere technique. Recently 2 oligodendroglioma cell lines were established from anaplastic oligodendrogliomas. These cell lines showed a codeletion of chromosomes 1p and 19q and an unbalanced translocation, t(1;19)(q10;p10). One of the cell lines (BT088) formed oligodendrogliomas in immunocompromised mice.^[@NOS135C98]^ Follow-up studies using the neurosphere culture method have shown that a cell line also can be established from an IDH1-mutant anaplastic oligoastrocytoma, which, as an orthotopic xenograft, showed rapid expansion in animals.^[@NOS135C99]^ These results clearly indicate that brain tumor stem cell lines with an endogenous R132H mutation in IDH1 can develop a tumor-initiating capacity as well as 2-hydroxygluterate production. Although it is too early to draw conclusions, neurobasal media may in the future represent a valuable tool for the development of xenografts from low-grade gliomas.

Human Biopsy Spheroid Xenograft Modeling {#s2c}
----------------------------------------

Biopsy spheroid xenograft models are based entirely on fresh brain tumor biopsies that are engrafted into immunodeficient animals using various techniques. The most prominent are heterotopic-to-orthotopic xenograft models and orthotopic biopsy spheroid models.

### Biopsy spheroid xenograft models {#s2c1}

In biopsy spheroid models the biopsy tissue is minced with surgical blades and transferred to flasks on agar-coated surfaces containing standard tissue culture serum-supplemented medium.^[@NOS135C100]^ Under these conditions, multicellular aggregates (spheroids) form within a short time. The spheroids maintain the original tissue architecture of the biopsy with endothelial outgrowths and host extracellular matrix components and resident macrophages.^[@NOS135C100]^ Other preserved traits include the same DNA ploidy and a similar percentage of proliferating cells as the tumor in situ.^[@NOS135C100]--[@NOS135C102]^ It has also been shown that such spheroids express similar aCGH profiles as the parental tumors.^[@NOS135C26]^

As orthotopic xenografts, the GBM biopsy spheroids display diffuse single cell infiltration both when co-cultured with fetal brain tissue in vitro and when implanted into rodent brains.^[@NOS135C16],[@NOS135C28],[@NOS135C102]--[@NOS135C104]^ The transplantation of GBM spheroids provides a reproducible tumor take rate close to 100% in immunodeficient rats. However, their growth rates and survival may vary among different tumors.^[@NOS135C16],[@NOS135C102],[@NOS135C104]^ In some instances, the initial engraftment may take up to 1 year, with 326 days being the longest period before symptoms appeared in the animals.^[@NOS135C102]^ The lesions grow slowly and depend largely on the host brain vasculature for oxygen and nutrients.^[@NOS135C104]^ Through further adaptation to the rodent brain by repeated transplantation cycles (giving rise to what is referred to as high-generation xenografts) in some of the tumors, the mitotic index increases, angiogenesis is induced, and necrotic areas and microvascular proliferations appear (Fig. [3](#NOS135F3){ref-type="fig"}C).^[@NOS135C102],[@NOS135C104]^ Also, the biopsy xenograft model preserves the invasive characteristics of the original tumor in early generations and will, by passaging, accumulate the other histological features of human GBM. Of note, our experience is that xenografts initiated from different patients may show different morphologies. In some GBM, angiogenesis appears rapidly after xenotransplantation, whereas in others, angiogenesis appears after serial animal passages. Moreover, phenotypes may be established that show only infiltrative growth with no signs of angiogenesis, even after repeated transplantations.^[@NOS135C16]^ These phenotypes have also been observed in mouse models.^[@NOS135C105]^ The differences in morphology are due most likely to differences in the genomic makeup among tumors and thus illustrate the fact that intertumor genomic heterogeneity can lead to different tumor phenotypes in vivo.

### Heterotopic-to-orthotopic xenograft models {#s2c2}

Invasive, intracranial tumors have also been established by a heterotopic-to-orthotopic approach, where tumors are first established by direct transplantation of human biopsies into the flanks of immunodeficient mice.^[@NOS135C106]^ Such xenografts can easily be serially passaged in the animals. Interestingly, when the tumors were established as intracranial tumors, a strong similarity to human tumors was observed, showing highly invasive tumors frequently displaying EGF receptor amplification. Also, DNA copy number and mRNA expression of a large panel of s.c. tumors showed striking similarities to human tumors.^[@NOS135C107]^ In these models, the authors observed, in most instances, a lack of necrotic features, and the tumors failed to show endothelial cell proliferation. This may be due to the relatively small tumor size obtained in the mouse brain, and it remains to be shown whether angiogenesis will appear if the tumors are established in a larger brain, eg, that of the nude rat.

### Advantages and pitfalls of the biopsy xenograft models {#s2c3}

Although continued in vivo passaging may change the histological appearance and gene expression profiles of the tumor cells within the biopsy spheroid xenografts, the original chromosomal aCGH profiles are grossly maintained, including amplification of the EGF receptor.^[@NOS135C104]^ Furthermore, recent data in our laboratory indicate that several clonally different subpopulations within the patient tumor are maintained over several in vivo passages, thus recapitulating the genetic heterogeneity of the original tumor in the xenograft (unpublished). This is of particular relevance, as it becomes increasingly clear that the maintenance of GBM heterogeneity in model systems is of paramount importance if we want to understand better how human gliomas grow in animals and how to use such models for reliable drug testing. Thus, the strength of this model relates to the eventual recapitulation of the histological traits of human GBM and the maintenance of genetic aberrations of the original lesion. However, not all xenografts encompass all the histological traits of GBM in situ at the same passage number. Furthermore, initial engraftment may take anywhere between 2 and 11 months.^[@NOS135C102]^ It should also be emphasized that biopsy spheroid xenograft models are highly variable, reflecting the heterogeneity of GBM among patients. This is an advantage, since they represent a clinically relevant model system yet a disadvantage in that standardization and experimental planning may be difficult. Of note, several early passage xenograft lesions resemble gliomatosis cerebri rather than GBM, and the acquisition of GBM-like histology usually takes at least 3 repeated passages in rat brains, taking anywhere between 8 to 18 months to acquire representative lesions reflecting human GBM. In the meantime, the patient might have succumbed to the original tumor or, in the case of successful clinical treatment, harbor an extensively selected tumor cell population not representative of the original lesion, and thus of the xenograft. This makes personalized medicine studies, using this animal model, difficult. Another hurdle relates to tumor immunology. Although nude rats have a well-developed innate immune system, they lack a normally developed thymus; thus a proper education of T cells does not occur.^[@NOS135C108]^

Therapeutic studies with this animal model performed in our lab have shown that gene therapy and antiangiogenic therapy reveal similar results, as observed in clinical studies, when it comes to treatment effects and survival and escape mechanisms.^[@NOS135C109],[@NOS135C110]^ These studies clearly highlight the clinical relevance of the biopsy-derived spheroid model.

Similar to the biopsy spheroid xenograft model, heterotopic-to-orthotopic xenografts show DNA copy numbers and mRNA expression signatures similar to those derived from the Cancer Genome Atlas.^[@NOS135C111]^ This includes genomic amplification and overexpression of known GBM oncogenes such as EGFR, MDM2, CDK6, and NYCN. These observations underline the value of propagating GBM tumors as subcutaneous xenografts for maintaining key molecular characteristics of human tumors and also for their use in targeting therapies. Moreover, the model may be simpler and more reliable than the spheroid biopsy model. However, when the tumors are grown at an orthotopic location, the lesions lack necrotic features and fail to show endothelial proliferation. Thus, not all histological features of human GBM are maintained.^[@NOS135C107]^

Genetically Engineered Mouse Models {#s2d}
-----------------------------------

Increased understanding of genomic alterations in primary brain tumors has led to the development of highly characterized GEM models of glioma based on specific genetic alterations observed in human tumors. In many instances, GEM models reflect the histopathology, etiology, and biology of human gliomas and represent an important experimental tool to uncover genetic alterations responsible for tumor initiation and progression, as well as for testing new therapeutic strategies.^[@NOS135C112]^

A number of comprehensive reviews have been published related to GEM modeling of human glioma,^[@NOS135C40],[@NOS135C113]--[@NOS135C115]^ so this section will only highlight the main advances in GEM development. During the last decade GEM models have been established involving complex strategies where multiple genes are gained or lost in specific cell types and at specific developmental time points. For instance, conditional strategies have been developed that regulate gene expression. This can be done in a tissue- and/or time-specific manner.^[@NOS135C116]--[@NOS135C118]^ For instance, tet-regulation or cre-inducible alleles of genes have been introduced that control the timing, duration, and specific cellular compartments for gene expression or inactivation. Moreover, somatic cell gene transfer has been developed using retroviral or adenoviral vectors delivering cre recombinase, eg, the RCAS/Tva system. This GEM model is based on the somatic introduction of multiple genes into a single mouse strain by using a receptor (Tva) for subgroup-A avian sarcoma leukosis viruses (ASLVs).^[@NOS135C119]^ Replication-competent avian leukosis virus splice acceptor (RCAS) viral vectors were derived from ASLVs; these vectors were genetically modified to accept insertion of various oncogenes of interest.^[@NOS135C120]^

Several GEM models have also been developed by altering key signaling pathways known to be disrupted in human gliomas. These pathways include, among others, those of platelet-derived growth factor, EGFR, Rb, Ras, and Akt.^[@NOS135C15],[@NOS135C121]--[@NOS135C123]^ A comprehensive overview of the various GEM models used for brain tumor modeling is provided in Table [1](#NOS135TB1){ref-type="table"}. Table 1.GEM models developed for the establishment of primary brain tumorsGenes InvolvedMouse System Used/PromoterTumor Type ModeledReferenceSV40 T-AgTransgenic mice/GFAPRADanks et al.^[@NOS135C13]^v-srcTransgenic mice/GFAPA, AA, schwannomaWeissenberger et al.^[@NOS135C115]^PDGF-BMoMuLV-injected C57B16 miceGBM, PNETUhrbom et al.^[@NOS135C116]^Nf1+/− and p53+/−Transgenic miceA, AA, GBMReilly et al.^[@NOS135C17]^K-ras and AktRCAS/tv-a/nestinGBMHolland et al.^[@NOS135C15]^PDGF-BRCAS/tv-a/ODai et al.^[@NOS135C117]^GFAP or nestinOAV^12^Ha-rasTransgenic mice/GFAPA, AA, GBMDing et al.^[@NOS135C118],[@NOS135C119]^Ink4a-Arf −/−, K-ras and AktRCAS/tv-a; GFAP or nestinSpindle cell GBM, giant cell GBMUhrbom et al.^[@NOS135C120]^Ink4a-Arf−/− and K-rasRCAS/tv-a; GFAP or nestinSarcoma-like lesionsUhrbom et al.^[@NOS135C120]^PTEN+/− and pRB inactivation through T~121~ expressionTransgenic mice/GFAPRAAXiao et al.^[@NOS135C121]^v-erb (EGFR) and Ink4a-Arf−/− p53+/−Transgenic mice/S100βO, AOWeiss et al.^[@NOS135C122]^V^12^Ha-ras and EGFRvIIITransgenic mice/GFAPO, OADing et al.^[@NOS135C123]^PTEN−/− and K-rasRCAS/tv-a; cre-lox system to delete PTEN/nestinGBMHu et al.^[@NOS135C124]^p53−/− and Nf1−/−GFAP-driven cre-lox system to delete Nf1A, AA, GBM, lymphomas, sarcomasZhu et al.^[@NOS135C125]^p53+/− and Nf1−/−p53+/− and Nf1+/−v-erb (EGFR)Transgenic rats/S100βMG, O, AOOhgaki et al.^[@NOS135C126]^V^12^Ha-ras and EGFRvIII (delivered by Ad)Transgenic mice/GFAPOA, A, AA, GBMWei et al.^[@NOS135C127]^PDGF and Ink4a−/−RCAS/tv-aO, AOTchougounova et al.^[@NOS135C128]^PDGF and Arf−/−Expression from GFAP or nestinPDGF onlyp53−/− and Nf1−/− and PTEN +/−GFAP-driven cre-lox system to delete Nf1 or PTENAA, GBMKwon et al.^[@NOS135C129]^PDGFB and Ink4a-Arf−/−RCAS/tv-a; cre-lox system to delete PTENA, AA, GBM, OAHambardzumyan et al.^[@NOS135C39]^PDGFB and Arf−/−GFAP or nestinPDGFB and p53−/−PDGFB onlyPDGFB and p53−/−Transgenic mice/GFAPGBM, OHede et al.^[@NOS135C130]^PDGFBTetracycline-regulated expression/GFAPOA, GBMHitoshi et al.^[@NOS135C131]^PDGFBCtv-a/CNPO, AO, OALindberg et al.^[@NOS135C132]^p53−/−GFAP-driven cre-lox system to delete p53AA, GBM, MBWang Y et al.^[@NOS135C133]^ Wang J et al.^[@NOS135C99]^p53−/− and Nf1−/−Transgenic mice/cre-lox system to remove stop casette before EGFR mini-genesGBMZhu et al.^134^EGFRvIII andInk4a−/− orPTEN−/−[^1]

Low-grade astrocytomas and oligodendrogliomas differ genetically from primary GBM and most other cancers in that they often sustain mutation of the isocitrate dehydrogenase 1 (*IDH1*) or 2 (*IDH2*) gene.^[@NOS135C124]^ The functional role of these mutations in glioma development is still unknown, but their occurrence appears to be an early mutational event, preceding 1p/19q loss in oligodendrogliomas and *p53* mutation in low-grade astrocytomas. Whether *IDH* mutations can initiate tumor development in a transgenic model or are necessary to sustain progression remains to be shown. Additional genetic changes that are hallmarks of these tumors, such as 1p/19q loss in oligodendroglioma and *p53* mutation in astrocytoma, are also missing in these models.^[@NOS135C15],[@NOS135C125]^

### Advantages and pitfalls of GEM models {#s2d1}

There are important fundamental differences between GEM models and xenograft models. GEM models address specific molecular events responsible for tumor initiation and progression. Therefore, GEM models have provided important new insight into the molecular events and pathways responsible for tumor initiation, progression, and metastasis. Another major strength of GEM models is their ability to model tumor/stroma interactions that contribute to malignancy, including factors that drive angiogenesis.^[@NOS135C126]^ In addition, GEM models show utility for studying the M1-to-M2 transition, through which an immune system that initially works to block tumor formation is usurped to contribute to malignant progression.^[@NOS135C127]^ Thus, since GEM models have been established in immunocompetent animals, they have expanded our knowledge of the important role of the microenvironment in tumor biology.^[@NOS135C128]^

GEM models also represent an excellent tool to dissect the minimum genetic alterations that are necessary for malignant transformation and to define the interplay among different pathways involved in oncogenesis.^[@NOS135C4]^ These models provide insight into the sequence of events of genetic alterations that occurs in response to a specific mutation. However, it is still an open question whether the involved genes truly mirror the tumor-initiating events in human gliomas in a tissue-specific manner (see below). As an example, the loss of *RB* is associated with retinoblastoma development in humans, whereas *RB* hemizygous mice develop an array of other cancer types but no retinoblastomas.^[@NOS135C129]^

By engineering targeted mutations in a cell- or tissue-specific as well as temporally limited manner, embryonic lethality issues can be avoided. Thus, tools are available to evaluate the role of any oncogene or tumor suppressor gene in neuro-oncogenesis, enabling a manipulation of the molecular factors that are known to be present in human gliomas. The defined genetic alterations that are present in these models represent a double-edged sword. On the one hand, we can study the effects of a given drug on a specific dysfunctional cancer-related pathway in a controlled manner without the interference of other altered interfering genes not known to the investigator. This is a clear advantage, since transplantable cancer cell lines are often poorly characterized at the molecular level. Therefore, these models could be applicable in proof of principle studies of drug selectivity. On the other hand, since the tumors are composed of cells with a number of specific homogeneously genetic changes, they cannot reflect the complete intratumoral genomic and phenotypic heterogeneity found in human gliomas. This is reflected in the vast number of GEM models developed (Table [1](#NOS135TB1){ref-type="table"}), which provides a clear indication that glial tumors can be established by an array of different genetic alterations. Yet, transgenic mice have been successful in recapitulating oligodendrogliomas and low-grade astrocytomas, where transplantable cell lines until recently have not been available.^[@NOS135C130]^ Another point is that therapeutic studies are often difficult to perform in GEM models because tumor initiation cannot be controlled unless cell lines derived from the models are used. Thus they are not highly reproducible models in relation to the time point of tumor initiation, which is needed for controlled therapeutic studies.

Glioma Animal Model Future Perspectives {#s2e}
---------------------------------------

At present it is clear that none of the animal models currently available fully recapitulates human glioma development and progression. Xenografts from chemically induced models as well as normal glioma cell lines grown in serum-supplemented media do not, to a large extent, reflect the genetic background of human gliomas, whereas xenografts derived from neurosphere cultures and from biopsy spheroid cultures as well as several GEM models more faithfully reflect the genotypic and phenotypic changes seen in human GBMs and recapitulate the infiltrative growth of human gliomas (Fig. [3](#NOS135F3){ref-type="fig"}).

The GEM and xenograft models derived from neurosphere cultures and human xenograft biopsies provide us with excellent tools to address a very important question: What are the exact mechanisms that lead to single tumor cell infiltration into the normal brain? With the advent of immunodeficient fluorescence labeled animals expressing enhanced green fluorescent protein and dsRed,^[@NOS135C131]^ we are able to separate and identify the tumor/host cellular compartments and study at the single cell level how tumor cells communicate within the host microenvironment^[@NOS135C132]^ (Fig. [4](#NOS135F4){ref-type="fig"}). Next, since neurosphere cultures in serum-free media seem to select for infiltrative cell phenotypes, we should be able to determine in detail whether the infiltrative cells within a human glioma represent a single clonal selection of cells within a heterogeneous tumor or are tumor cells that show adaptive capacities to specific microenvironmental cues present in the brain/tumor interfaces, or whether both modes of action occur during tumor progression.^[@NOS135C91]^ In this context it should be emphasized that many research groups have focused on identifying phenotypic markers that characterize specific tumor cell phenotypes, which have then been associated with a specific biological property. Frequently, such studies ignore the fact that cells in general may change or adapt their phenotype within specific cellular microenvironments and that stochastic events may provide a phenotypic equilibrium within a heterogeneous population of cancer cells.^[@NOS135C133]^ Thus it should be emphasized that the phenotype is not a static entity, and it is clear that a future focus on epigenetic mechanisms will provide valuable clues as to what extent the phenotype can change based on microenvironmental factors. Fig. 4.Strategy for separation and analysis of the tumor/host cellular compartments. With the development of immunodeficient mice expressing enhanced green fluorescent protein, it is at present possible to completely separate and immunophenotype the cells in the tumor/host cellular compartments.^137^ This technique shows considerable promise in elucidating mechanisms involved in tumor/host cell communication.

It would also be highly interesting to compare in detail the phenotypes developed in the xenograft models with those obtained in various infiltrative GEM models. This would be of particular importance in the search for the best GEM model that reflects human disease. Such information will also provide valuable clues for delineating specific mechanisms involved in human glioma initiation and progression (Fig. [5](#NOS135F5){ref-type="fig"}). If such comparisons are performed in detail, it could, in the coming years, lead to the identification of new and effective treatment modalities that will specifically target the tumor-initiating cells as well as the infiltrative tumor cell within human gliomas. Fig. 5.Unraveling the mechanisms of tumor invasion and progression from animal models. Further development in the field of neuro-oncology must integrate current molecular knowledge from human tumors as well as biological knowledge from GEM and spheroid and stem/progenitor cell--based xenotransplantation models. The search for common denominators will most likely lead to the identification of robust therapeutic targets that should eventually be validated in human GBM.
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[^1]: Abbreviations: SV40 T-Ag, simian vacuolating virus 40 large transforming-antigen; V^12^Ha-ras, constitutively active human Ras; v-src, viral-sarcoma; GFAPR, glial fibrillary acidic protein--5′ regulatory domain; RCAS/tv-a, replication competent avian leukosis virus splice acceptor/receptor for avian leukosis virus subgroup A; O, oligodendroglioma; AO, anaplastic oligodendroglioma; OA, oligoastrocytoma; MB, medulloblastoma; GBM, glioblastoma multiforme; MoMuLV, Moloney murine leukemia virus; CNP, 2′,3′-cyclic nucleotide 3′-phosphodiesterase; Ad, adenovirus.
